Decoy Therapeutics Inc.
For the period ended Jun 30, 2026. Filed Aug 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 12, 2026
DCOY$1.11+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
| Three Months EndedJune 30, | Six Months EndedJune 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Grant Revenue | $227,629 | - | 227,629 | - |
| Operating expenses: | ||||
| Research and development | $1,304,345 | $116,383 | $2,054,158 | $191,915 |
| General and administrative | 1,326,676 | 849,182 | 2,860,602 | 2,492,345 |
| Total operating expenses | 2,631,021 | 965,565 | 4,914,760 | 2,684,260 |
| Loss from operations | (2,631,021) | (965,565) | (4,914,760) | (2,684,260) |
| Interest income and other, net | $29,592 | $7,740 | 88,703 | 16,902 |
| Net loss | $(2,373,800) | $(957,825) | $(4,598,428) | $(2,667,358) |
| Net loss per share attributable to common stockholders — basic and diluted | $(4.46) | $(81.21) | $(8.64) | $(253.72) |
| Total net loss per share | $(4.46) | $(81.21) | $(8.64) | $(253.72) |
| Weighted-average number of common shares used in net loss per share attributable to common stockholders — basic and diluted | 531,968 | 11,794 | 531,968 | 10,513 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.